logo
Plus   Neg
Share
Email

EC Approves Marketing Authorization Of DACOGEN For Acute Myeloid Leukemia

Astex Pharmaceuticals Inc. (ASTX) said that Janssen-Cilag International NV was notified that the European Commission has approved the marketing authorization for DACOGEN for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia or AML, according to the World Health Organization classification, who are not candidates for standard induction chemotherapy. Also, DACOGEN has been granted Orphan Drug designation to treat AML.

The data in support of the marketing authorization is based on the Phase 3 DACO-016 study that compared decitabine to patients' choice with physician advice of either supportive care or low-dose cytarabine in the treatment of older patients with AML.

DACO-016 was a Phase 3, randomized, open-label trial, in newly diagnosed patients =65 years of age with de novo or secondary AML and poor- or intermediate-risk cytogenetics.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Kimberly-Clark Corp. (KMB) reported third-quarter adjusted earnings per share of $1.71, an increase of 7 percent compared to net income per share of $1.60, prior year. On average, 16 analysts polled by Thomson Reuters expected the company to report profit per share of $1.64 for the quarter. Analysts'... South Korean IT services company Samsung SDS has joined with Dutch bank ABN AMRO and Port of Rotterdam Authority for a trial project that applies blockchain to shipping and logistics business. Samsung SDS, the IT arm of South Korean Conglomerate Samsung, and ABN AMRO will connect their blockchain platforms Nexledger and Corda, respectively, with the pilot. Dutch consumer electronics giant Philips Electronics NV reported Monday lower net profit in its third quarter mainly due to the deconsolidation of Lighting. Profit from continuing operations climbed with improved margin and sales. Order intake also increased. Looking ahead, the company reiterated targets for the 2017-2020 period of 4-6 percent comparable sales growth.